All In Biotech

Drug Trial Radar · NCT06987500

A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of XNW29016 Tablets in Advanced Solid Tumors With Failed Standard Treatment

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Apr 11, 2025

Primary completion

Feb 14, 2027

Study completion Aug 16, 2027

Sponsor

Lead sponsor
Evopoint Biosciences Inc.Industry
Sponsor type
Industry
Collaborators
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
First posted
May 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the safety, tolerability, and efficacy of XNW29016 in participants with advanced solid tumors .

Conditions

  • Tumor, Solid

Interventions

  • XNW29016Drug

    Oral Medication. The study set 7 dose level cohorts in dose escalation part.

  • XNW29016Drug

    Oral Medication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ph Ia/Ib: Overall safety profile including adverse eventsTime frame: Baseline up to approximately 2 years
  2. Ph Ia/Ib: Recommended phase 2 doses (RP2D) of XNW29016Time frame: Approximately 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 17 South Li, Panjiayuan, Chaoyang District, Beijing City.

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.